Literature DB >> 32894276

GREB1 regulates PI3K/Akt signaling to control hormone-sensitive breast cancer proliferation.

Corinne N Haines1,2, Hope D Klingensmith1, Makanko Komara2, Craig J Burd1,2.   

Abstract

Over 70% of breast cancers express the estrogen receptor (ER) and depend on ER activity for survival and proliferation. While hormone therapies that target receptor activity are initially effective, patients invariably develop resistance which is often associated with activation of the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. While the mechanism by which estrogen regulates proliferation is not fully understood, one gene target of ER, growth regulation by estrogen in breast cancer 1 (GREB1), is required for hormone-dependent proliferation. However, the molecular function by which GREB1 regulates proliferation is unknown. Herein, we validate that knockdown of GREB1 results in growth arrest and that exogenous GREB1 expression initiates senescence, suggesting that an optimal level of GREB1 expression is necessary for proliferation of breast cancer cells. Under both of these conditions, GREB1 is able to regulate signaling through the PI3K/Akt/mTOR pathway. GREB1 acts intrinsically through PI3K to regulate phosphatidylinositol (3,4,5)-triphosphate levels and Akt activity. Critically, growth suppression of estrogen-dependent breast cancer cells by GREB1 knockdown is rescued by expression of constitutively activated Akt. Together, these data identify a novel molecular function by which GREB1 regulates breast cancer proliferation through Akt activation and provides a mechanistic link between estrogen signaling and the PI3K pathway. Published by Oxford University Press 2020.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32894276      PMCID: PMC7791615          DOI: 10.1093/carcin/bgaa096

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  40 in total

1.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Authors:  Todd W Miller; Bryan T Hennessy; Ana M González-Angulo; Emily M Fox; Gordon B Mills; Heidi Chen; Catherine Higham; Carlos García-Echeverría; Yu Shyr; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  Akt activation by growth factors is a multiple-step process: the role of the PH domain.

Authors:  A Bellacosa; T O Chan; N N Ahmed; K Datta; S Malstrom; D Stokoe; F McCormick; J Feng; P Tsichlis
Journal:  Oncogene       Date:  1998-07-23       Impact factor: 9.867

4.  p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype.

Authors:  Adam Freund; Christopher K Patil; Judith Campisi
Journal:  EMBO J       Date:  2011-03-11       Impact factor: 11.598

5.  PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer.

Authors:  M G Ghosh; D A Thompson; R J Weigel
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

Review 6.  Activation of AKT kinases in cancer: implications for therapeutic targeting.

Authors:  Alfonso Bellacosa; C Chandra Kumar; Antonio Di Cristofano; Joseph Robert Testa
Journal:  Adv Cancer Res       Date:  2005       Impact factor: 6.242

Review 7.  A review of clinical aspects of breast cancer.

Authors:  Shai Libson; Marc Lippman
Journal:  Int Rev Psychiatry       Date:  2014-02

8.  GREB 1 is a critical regulator of hormone dependent breast cancer growth.

Authors:  James M Rae; Michael D Johnson; Joshua O Scheys; Kevin E Cordero; José M Larios; Marc E Lippman
Journal:  Breast Cancer Res Treat       Date:  2005-07       Impact factor: 4.872

9.  Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

Authors:  Chad J Creighton; Xiaoyong Fu; Bryan T Hennessy; Angelo J Casa; Yiqun Zhang; Ana Maria Gonzalez-Angulo; Ana Lluch; Joe W Gray; Powell H Brown; Susan G Hilsenbeck; C Kent Osborne; Gordon B Mills; Adrian V Lee; Rachel Schiff
Journal:  Breast Cancer Res       Date:  2010-06-22       Impact factor: 6.466

10.  The genomic landscape of breast cancer as a therapeutic roadmap.

Authors:  Matthew J Ellis; Charles M Perou
Journal:  Cancer Discov       Date:  2013-01       Impact factor: 39.397

View more
  1 in total

1.  Comprehensive Analysis of GDF10 Methylation Site-Associated Genes as Prognostic Markers for Endometrial Cancer.

Authors:  Jingyi Fan; Huaijun Zhou
Journal:  J Oncol       Date:  2022-10-10       Impact factor: 4.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.